{"name":"Tricida, Inc.","slug":"tricida-inc","ticker":"","exchange":"","domain":"","description":"Tricida, Inc. was a biopharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). The company discontinued its development program for TRC101 in 2021.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":115364000,"netIncome":-176566000,"cash":21113000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQYlV6Tkt5eURmTjFsVEpZbXJpOFcyQ1BHdm0tcFZXT1JtQ1dBM3JYbnc3Tzc0RTEzbl9qbEx5UkMyODJVd0x3S3NqcTFndTNqbmpLSXJ3WUVkRFF4Z1hxU2psaDlHWV9RRUlCQ0xZa0xFeWEyeW5aSFFrNWFGUV9CYUlWbWJ2XzRmVFk5SVp2Q19lcmV1N1IyRnBfbmU0NkVIQXIwRWRCZWNsS3RfSVE?oc=5","date":"2024-03-12","type":"pipeline","source":"Bloomberg Law News","summary":"Tricida Investor Suit to Proceed Over Two Kidney Drug Statements - Bloomberg Law News","headline":"Tricida Investor Suit to Proceed Over Two Kidney Drug Statements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOWnFtVFFpWFViNnBXVWU0bEczNm0zS2kwNDNnRkZ1QzUzTDY1S1M2RXBjZlNIRURCZWM1NXFMb2tzdnhfVGFQY0U1d0JraHhsOTRlVXJ5TjVzMkt3T1MyUFVfaXZTMVN2dFFxUGdCbEpBOF84cloyX1A1Z0xXTGY0bWdSZkJQWkFOd21tZHBCWU93TmcwNTFPbVdNTy0waW55blJsMF80RDBfVEc4VE1VN1Z3?oc=5","date":"2023-10-10","type":"pipeline","source":"The Business Journals","summary":"Biotech's 2023 ghosts haunt efforts to exorcise downturn - The Business Journals","headline":"Biotech's 2023 ghosts haunt efforts to exorcise downturn","sentiment":"neutral"},{"date":"2023-06-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-05-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-04-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-03-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-03-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOOGlrbEdxbmpDSzN0S0x0TThyY0FnZDJhRGNySTRqcGVtWUN6dWdEUXNRNzZzdmtkd2p2LV9xd2ptV3ItbHplYzhkVm5fSHlGaXBycmRxX05meWNiVEJnWlU2Q2hFOGpXYUwtb2MxTnlIYXg4S1ZXeUU3UnlhOE9mdTRLYlRad0JrMkk4djFtUnEwZnlTc1dubWw4OF9pLWfSAVZBVV95cUxOQzVUMFd0UVhORjNtNlREUzZGNk9RRllYQzRmME94aWdJS01LaGpkQk1RSnlOcDh3T09xR0Uza2pOMUtiNTlqbE9xdkxnSnZJUmNkVXgydw?oc=5","date":"2023-02-21","type":"deal","source":"Law360","summary":"Renibus Buys Tricida's Kidney Drug Veverimer In Ch. 11 Sale - Law360","headline":"Renibus Buys Tricida's Kidney Drug Veverimer In Ch. 11 Sale - Law360","sentiment":"neutral"},{"date":"2023-02-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-01-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNMm1jci1aRF9pXzVma2ZzZGdOVlpWUFZlWXJjXzZzY3V2LUR2WXRfeHROeEdFNWxhMkVNbWp0QUx2d3o0bmZRMml2ajRxZHNienhmV1dURzJpc2tKTmcyOXJZQ2o3RnFEQ0h3OVlmVThiVEtCMWVKV2NoTzVqRGdzRkQzY1oweDZGcUI0ZWFXSQ?oc=5","date":"2022-12-14","type":"trial","source":"AlphaSense","summary":"300+ transcripts from JPM's 39th Annual Healthcare Conference - AlphaSense","headline":"300+ transcripts from JPM's 39th Annual Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPSFZ4NGpVemFrRlZwX2ZhY0dUdUd0N0JCc1VNUjNLdk5NSUk5SEhrNHJSMWFtemEzdEluWHhkRUhzRjIwRFcwRU16WWFmc1Vabldick92OUZjMzhSWGQxbERoTVhvd0dYanJyZjVxN3B3WDRKVGhTbk9IOFJpcTRZYkNMQkFoMWpvaUVzVXd4OFBsQQ?oc=5","date":"2022-11-16","type":"pipeline","source":"BioSpace","summary":"Reeling from CKD Flop, Tricida Downsizes by Nearly 60% - BioSpace","headline":"Reeling from CKD Flop, Tricida Downsizes by Nearly 60%","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":115364000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-176566000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":21113000,"cashHistory":[],"totalAssets":168506000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}